H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to 0c from $10 and keeps a Sell rating on the shares. The firm now sees zero intrinsic value for the shares after the FDA requested the U.S. market removal of Elevidys. In the absence of future Elevidys. revenues, there is no intrinsic value left in Sarepta shares, the analyst tells investors in a research note. Sarepta in premarket trading is down 30c to $13.78.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta downgraded to Neutral from Outperform at Mizuho
- JPMorgan, Starbucks, HPE, Sarepta, Elevance: Trending by Analysts
- Sarepta drops another 5% to $13.37 after downgrades, FDA probe
- Sarepta says will continue to ship Elevidys to ambulant population
- FDA investigating risk of acute liver failure with Sarepta gene therapies